Optera Therapeutics is Biotechnology in United States that focus on engineered T cells business. Founded in 2018. They cover business area such as developer, autologous cell therapy, cancer cell therapy, immunotherapy, patient, their own immune cell, chimeric antigen receptor, (CAR-T, (TCR, tumor-infiltrate lymphocyte, TIL, endogenous t cell, ETC, physician, solid tumor, breast, lung, colon, pancrea, skin.
2018
( 6 years old in 2024 )
Engineered T Cells
-
5858 Horton Street
Suite 500
Emeryville, CA
United States
Private
developerautologous cell therapycancer cell therapyimmunotherapypatienttheir own immune cellchimeric antigen receptor(CAR-T(TCRtumor-infiltrate lymphocyteTILendogenous t cellETCphysiciansolid tumorbreastlungcolonpancreaskin
* We use standard office opening hours in near Optera Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Optera Therapeutics is Biotechnology business from United States that founded in 2018 (6 years old in 2024), Optera Therapeutics business is focusing on Engineered T Cells.
Optera Therapeutics headquarter office and corporate office address is located in 5858 Horton Street Suite 500 Emeryville, CA United States.
Optera Therapeutics was founded in United States.
In 2024, Optera Therapeutics is currently focus on engineered T cells sector.
Above is snippet of Google Trends for "engineered T cells" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Optera Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
